

Version With Markings To Show Changes Made

IN THE CLAIMS

The following claims have been amended as follows:

1. (Amended) A composition for the percutaneous administration of an opioid analgesic which [includes a component susceptible to co-extraction with the opioid analgesic and when administered orally or by injection after extraction by an abuser will distress the abuser] comprises a therapeutic amount of the opioid analgesic in association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane and a quantity of a distressing substance which is non-permeant through human skin, said distressing substance when ingested orally or as parenteral bolus injection together with the opioid analgesic will produce a distressful reaction in the recipient.
2. (Amended) A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in association with a vehicle [or means] for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane, [and] a quantity of a distressing substance and a membrane which is permeable to the opioid analgesic and non-permeable to the distressing substance, said distressing substance not penetrating the skin of a human patient when the composition is applied to the skin of said patient and said distressing substance [which,] when ingested orally or as parenteral bolus injection together with the opioid analgesic will produce a distressful reaction in the recipient.
3. (Amended) A composition according to claim 1 , wherein the distressing substance is selected from the group consisting of emetics, nauseants and flavouring substances [or bitter substances].
4. (Amended) A composition according to claim 2 [3], wherein the distressing substance is selected from the group consisting of ergolides, [;] quaternary ammonium compounds, [; non-permeant] opioid antagonists, [; other opioid antagonists;] emetics, [;] and atropine or salts thereof.
5. (Amended) A composition according to claim 1, wherein the distressing substance is [non-permeant and is] incorporated in a vehicle being the same vehicle as for the opioid analgesic.

The following claims have been added:

16. (New) A composition according to claim 2, wherein the distressing substance is incorporated in a vehicle being the same vehicle as for the opioid analgesic.

17. (New) A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane, and a quantity of a distressing substance selected from the group consisting of ergolides, quaternary ammonium compounds, atropine or salts thereof, and mixtures thereof, said distressing substance separated from the opioid analgesic and not penetrating the skin of a human patient when the composition is applied to the skin of said patient, said distressing substance when ingested orally or as parenteral bolus injection together with the opioid analgesic will produce a distressful reaction in the recipient.